Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.35 |
| ▸ | GIPR | P48546 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469837 | 0.90 | P2RX3 (0.41) | SMN1; SMN2MAPTLMNAHDAC1HDAC6 | |
| SCHEMBL22830598 | 0.88 | GPR119 (0.37) | SMN1; SMN2MAPTLMNAHDAC1HDAC6 | |
| SCHEMBL22845200 | 0.86 | GCGR (0.38) | GCGRMAPTPOLBGIPRSCN9A | |
| SCHEMBL24483837 | 0.85 | GCGR (0.38) | GCGRMAPTPOLBGIPRSCN9A | |
| SCHEMBL24469917 | 0.84 | HDAC1 (0.36) | SMN1; SMN2MAPTLMNAS1PR2HDAC1 | |
| SCHEMBL22845314 | 0.83 | GCGR (0.41) | GCGRMAPTPOLBGIPRKCNH2 | |
| SCHEMBL24470081 | 0.82 | GPR119 (0.36) | SMN1; SMN2MAPTLMNAS1PR2HDAC1 | |
| SCHEMBL22845225 | 0.81 | MAPT (0.46) | MAPTPOLBHDAC1HDAC6P2RX3 | |
| SCHEMBL22845220 | 0.79 | ABHD6 (0.39) | GCGRMAPTPOLBGPR119LIPE | |
| SCHEMBL24469916 | 0.78 | GPR119 (0.34) | SMN1; SMN2MAPTLMNAS1PR2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GCGR 1314/4885SMN1; SMN2 1114/4885MAPT 651/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GCGR 1314/4885SMN1; SMN2 1114/4885MAPT 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.